FARMINGDALE, N.Y., March 13, 2017 /PRNewswire/ -- Misonix,
Inc. (NASDAQ: MSON), a provider of minimally invasive
therapeutic ultrasonic medical devices that enhance clinical
outcomes, announced today that it will conduct a conference call to
review the financial results for the first half of fiscal year
2017, ended December 31, 2016, on
Tuesday, March 14, 2017 at
9:00 am ET.
Interested parties can access the conference call by dialing
(844) 861-5497 or (412) 317-6579 or can listen via a live Internet
webcast, which is available in the Investor Relations section of
the Company's website at www.misonix.com.
A teleconference replay of the call will be available for three
days at (877) 344-7529 or (412) 317-0088, confirmation # 10103113.
A webcast replay will be available in the Investor Relations
section of the Company's website at www.misonix.com for 30
days.
About Misonix
Misonix, Inc. designs, develops,
manufactures and markets therapeutic ultrasonic medical devices.
Misonix's therapeutic ultrasonic platform is the basis for several
innovative medical technologies. Addressing a combined market
estimated to be in excess of $1.5
billion annually; Misonix's proprietary ultrasonic medical
devices are used in spine surgery, neurosurgery, orthopedic
surgery, wound debridement, cosmetic surgery, laparoscopic surgery,
and other surgical and medical applications. Additional
information is available on the Company's website at
www.misonix.com.
Safe Harbor Statement
With the exception of
historical information contained in this press release, content
herein may contain "forward looking statements" that are made
pursuant to the Safe Harbor Provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based on
management's current expectations and are subject to uncertainty
and changes in circumstances. Investors are cautioned that
forward-looking statements involve risks and uncertainties that
could cause actual results to differ materially from the statements
made. These factors include general economic conditions, delays and
risks associated with the performance of contracts, risks
associated with international sales and currency fluctuations,
uncertainties as a result of research and development, acceptable
results from clinical studies, including publication of results and
patient/procedure data with varying levels of statistical
relevancy, risks involved in introducing and marketing new
products, potential acquisitions, consumer and industry acceptance,
litigation and/or court proceedings, including the timing and
monetary requirements of such activities, the timing of finding
strategic partners and implementing such relationships, regulatory
risks including approval of pending and/or contemplated 510(k)
filings, the ability to achieve and maintain profitability in the
Company's business lines, the impact of the pending investigation
by the Department of Justice and Securities Exchange Commission,
and other factors discussed in the Company's Annual Report on Form
10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports
on Form 8-K. The Company disclaims any obligation to update its
forward-looking relationships.
Company
Contact:
|
Investor
Contacts:
|
Joseph
Dwyer
|
Robert Blum, Joe
Dorame, Joe Diaz
|
Misonix,
Inc.
|
Lytham Partners,
LLC
|
631-694-9555
|
602-889-9700
|
invest@misonix.com
|
mson@lythampartners.com
|
www.misonix.com
|
www.lythampartners.com
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/misonix-inc-to-review-financial-results-for-first-half-of-fiscal-year-2017-on-tuesday-march-14-2017-300422699.html
SOURCE Misonix, Inc.